The Medical Letter on Drugs and Therapeutics
Another Subcutaneous Immune Globulin (Cuvitru) for Primary Immunodeficiency (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved a subcutaneously administered 20% solution of human immune globulin (Cuvitru – Shire) for replacement therapy in patients ≥2 years old with a primary humoral immunodeficiency. Hizentra (CSL Behring), another subcutaneously administered 20% immune globulin solution, was approved in 2010 for the same indication. The IgG component of Cuvitru is similar to that of Gammagard Liquid and HyQvia, two subcutaneously administered 10% immune globulin formulations also manufactured by Shire and approved for treatment of primary immunodeficiencies.

PRIMARY IMMUNODEFICIENCIES — Primary humoral immunodeficiencies include common variable immunodeficiency (CVID), X-linked or congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.1 These disorders are usually congenital, presenting in ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Another Subcutaneous Immune Globulin (Cuvitru) for Primary Immunodeficiency (online only)
Article code: 1521e
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian